Is the new drug Pavblu approved for treating diabetic macular edema?
Pavblu is a brand name for aflibercept, a VEGF inhibitor drug. The U.S. Food and Drug Administration (FDA) has approved Pavblu for several eye conditions, including diabetic macular edema (DME). This means doctors can prescribe it to treat DME. Other aflibercept products, such as Eylea HD, are also approved for DME.
What the research says
The FDA approval for Pavblu specifically lists diabetic macular edema (DME) as one of its approved uses 2. This is based on clinical trials showing that aflibercept, the active ingredient in Pavblu, is effective for DME. For example, the PHOTON trial compared aflibercept 8 mg given every 12 or 16 weeks to the standard 2 mg every 8 weeks in patients with DME. After 96 weeks, visual gains were similar across groups, and the 8 mg dose allowed fewer injections 3. Another analysis from the KINGFISHER study found that brolucizumab (a different anti-VEGF drug) and aflibercept both improved vision in DME patients, whether they had prior treatment or not 6. Additionally, a systematic review of aflibercept biosimilars showed they match the original drug's safety and effectiveness for DME 4. While Pavblu is a newer brand, it contains the same active ingredient as other approved aflibercept products.
What to ask your doctor
- Is Pavblu (aflibercept) a good option for my diabetic macular edema?
- How does the dosing schedule for Pavblu compare to other treatments I might use?
- What are the possible side effects of Pavblu, and how do they compare to other anti-VEGF drugs?
- Are there any reasons I should not use Pavblu based on my other health conditions or medications?
- How will we monitor my response to Pavblu treatment?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.